natgillin/translations-raw huggingface dataset:
The antibody according to claims 1, characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 9, a CDR2 region of SEQ ID NO: 10, and a CDR1 region of SEQ ID NO: 11, and the light chain variable domain comprises a CDR3 region of SEQ ID NO:12, a CDR2 region of SEQ ID NO: 13, and a CDR1 region of SEQ ID NO: 14, or the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:69, a CDR2 region of SEQ ID NO: 70, and a CDR1 region of SEQ ID NO:71, and the light chain variable domain comprises a CDR3 region of SEQ ID NO: 72, a CDR2 region of SEQ ID NO:73, and a CDR1 region of SEQ ID NO:74, or 
varijabilna domena jakog lanca obuhvaća područje CDR3 od SEQ ID NO:41, područje CDR2 od SEQ ID NO:42, i područje CDR1 od SEQ ID NO:43, te varijabilna domena slabog lanca obuhvaća područje CDR3 od SEQ ID NO:44, područje CDR2 od SEQ ID NO:45, i područje CDR1 od SEQ ID NO:46, ili varijabilna domena jakog lanca obuhvaća područje CDR3 od SEQ ID NO:49, područje CDR2 od SEQ ID NO:50, i područje CDR1 od SEQ ID NO:51, te varijabilna domena slabog lanca obuhvaća područje CDR3 od SEQ ID NO:52, područje CDR2 od SEQ ID NO:53, i područje CDR1 od SEQ ID NO:54.
A peptide according to any one of claims 1 to 4, the cell according to claim 7, or an activated cytotoxic T lymphocyte according to claim 10 for use in the treatment of cancer. 
Terapijski učinkovita količina farmaceutskog sastava iz bilo kojeg od prethodnih zahtjeva za uporabu u liječenju ili sprječavanju karcinoma kod pacijenata, Farmaceutski sastav za uporabu prema zahtjevu 11, naime kao cjepivo protiv karcinoma.
The method according to the claim 10, wherein the L1 block has L1 signaling information for signaling the data slice. 
Uređaj prema zahtjevu 11 ili 12, naznačen time, što LI blok ima LI signalizacijsku informaciju za signaliziranje podatkovnog odsječka.
In one embodiment of the present invention the compound as described herein is characterized in that said target opioid receptor is selected from the group comprising of the mu-receptor, delta-receptor and kappa-receptor. 
Spoj namijenjen upotrebi kao medikament u skladu s patentnim zahtjevom 8, naznačen time što se navedeni ciljani opioidni receptor bira iz skupine koju čine receptor u, receptor d i receptor x.
Pull-out mechanism according to one or more of claims 1-3 characterised in that incliningly extending web parts (26; 26'; 26"), which can serve for the affixation of the bearing holders (12, 22; 12'; 12") in relation to the intermediate rail (10; 10'; 10"), are provided locally on the intermediate rail (10; 10'; 10"). 
Mehanizam za izvlačenje ladice u skladu s jednim ili s više patentnih zahtjeva 1 do 3, naznačen time što su predviđeni na pojedinim mjestima na među-tračnici (10; 10; 107) dijelovi staze koji se prostiru pod nagibom (26, 26, 26") 1 koji mogu služiti za učvršćenje držača ležaja (12, 22; 12%; 12%) u odnosu na među-tračnicu (10; 10%; 107).
Indeed there is evidence that lithium, an uncompetitive inhibitor of GSK3B, enhances neuritogenesis in some models and also increases neuronal survival, through the induction of survival factors such as Bcl-2 and the inhibition of the expression of proapoptotic factors such as P53 and Bax. 
I doista, postoji dokaz da litij, nekompetitivni inhibitor GSK3R, pojačava neuritogenezu u nekim modelima, a također povećava i preživljenje neurona, indukcijom čimbenika preživljavanja, poput Bcl-2, te inhibicijom eksprezije proapoptotskih čimbenika, poput P53 i Bax.
1, a belling machine for forming sockets on the ends of pipes made of thermoplastic material comprises a forming chamber 1, for the insertion and forming of a socket on the heated end 20 of a pipe 2 made of thermoplastic material on which a socket is to be formed. 
- < komore za oblikovanje (1), za umetanje i oblikovanje čahure na zagrijanom završetku (20) cijevi (2) izrađene od termoplastičnog materijala na kojoj se treba oblikovati čahura;
A pharmaceutical composition comprising compound of formula IIB: or a pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, wherein: 
Farmaceutski sastav koji sadrži spoj formule IIB: "TI ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, pri čemu:
The herbicide composition as claimed in claim 3 where the two different ALS inhibitors are iodosulfuron-methyl and foramsulfuron. 
Herbicidna kombinacija prema zahtjevu 4 naznačena time da su inhibitori ALS odabrani iz skupine koja sadrži jodosulfuron-metil i foramsulfuron.
reacting the aminooxy group of the oligosaccharide with the at least one carbonyl group of the protein, thereby coupling the oligosaccharide to the protein, wherein the oligosaccharide is an oligosaccharide of Formula IV: 
reakciju prve reaktivne skupine oligosaharida s drugom reaktivnom skupinom aminooksi spoja, te se na taj način priprema oligosaharid koji sadrži aminooksi skupinu. Postupak prema patentnom zahtjevu 9, naznačen time što je aminooksi spoj
A pharmaceutical composition comprising the bispecific antibody or bispecific antibody fragment thereof of any one of Claims 1 or 2 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak naznačen time da sadrži bispecifično antitijelo ili njegov bispecifični fragment antitijela prema bilo kojem zahtjevu 1 ili 21 farmaceutski prihvatljiv nosač.
The composition of para 9, wherein the isolated monomeric platinum complex does not bind DNA. The composition of para 11, wherein the isolated monomeric platinum complex triggers overexpression of fas and fas-related transcription factors. The composition of para 11, wherein the isolated monomeric platinum complex triggers overexpression of proapoptotic genes. 
Pripravak za uporabu u postupku liječenja raka prema zahtjevu 7, naznačen time da izolirani monomerni kompleks platine ne veže DNK. Pripravak za uporabu u postupku liječenja raka prema zahtjevu 7, naznačen time da izolirani monomerni kompleks platina aktivira prekomjernu ekspresiju fas i fas-srodnih transkripcijskih faktora, ili proapoptotičkih gena.
2 was shown connected to LED diode 112, now is connected to resistor 1111a, which supplies the anode of LED diode 112. 
2 bio prikazan spojen na LED diodu 112, sada je spojen na otpornik 1111a, koji napaja anodu LED diode 112.
a C1-C3 alkyl group, branched or unbranched, saturated or unsaturated, optionally substituted by a fluorine atom, 
- Cr-Cz-alkilna skupina koja je razgranana ili ravnolančasta, zasićena ili nezasićena, a može biti supstituirana atomom fluora,
oxopiperidyl, said oxopiperidyl being unsubstituted or substituted with one, two or three substituents independently selected from C1-6alkyl and hydroxy; 
oksopiperidil, pri čemu je navedeni oksopiperidil nesupstituiran ili supstituiran s jednim, dva ili tri supstituenta neovisno odabrana iz C1−6alkila i hidroksi skupine;
having unusually slow rates of progression of disease despite the presence of an established clinical diagnosis of probable Alzheimer's disease; or 
(1v) ima neuobičajeno spore brzine napredovanja bolesti usprkos prisutnosti utvrđene kliničke dijagnoze vjerojatne Alzheimerove bolesti.
A compound of formula (IV), or a pharmaceutically acceptable salt thereof, Or a tautomeric form thereof wherein: 
Spoj formule (IV) ili njegova farmaceutski prihvatljiva sol, [image] ili njegov tautomerni obliknaznačen time da:
An oral formulation in tablet form according to claim 6, wherein the glidant is 0.1% to 2.0% weight percent colloidal silicon dioxide. 
Oralna formulacija u obliku tablete u skladu s patentnim zahtjevom 6, naznačena time što je sredstvo za klizanje 0,1% do 2,0%, težinski, koloidni silicijev dioksid.
The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art. 
Sterilni vodeni mediji koji se koriste na raspolaganju su putem standardnih tehnika poznatih osobama 1z struke.
10/140,596 illustrates certain ways that flow could be controlled from bottle 20. 
10/140,596 prikazuje nckoliko načina kako sc može regulirati isticanje iz boce 20.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, le kao komponentu (B) fluopiram.
DEFINITIONS The following definitions apply to terms as used herein 
čime se dobiva spoj Formule X: b. skidanje zaštite sa spoja Formule X, čime se dobiva spoj Formule XI:
(a3) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 3; 
(a3) H-lanac protutijela koji se sastoji od aminokiselinske sekvence SEQ ID NO: 3;
A nucleic acid molecule comprising nucleotides 19 to 2298 of SEQ ID NO:16. 
Agonistički protein TRAIL receptora koji sadrži polipeptid koji se sastoji od sekvence aminokiseline navedene u SEQ ID NO: 19.
methylating the compound according to formula (1), or salt thereof, to obtain a compound according to formula (2), or salt thereof, 
43 b) metilacija spoja prema formuli (1) ili njegove soli, kako bi se dobio spoj u skladu sa sljedećom formulom (2) ili 15
A pharmaceutical composition according to claim 1 in the dosage form of a capsule, a tablet or a film-coated tablet. 
Farmaceutski pripravak u skladu sa zahtjevom 1, naznačen time, da je u dozirnom obliku kapsule, tablete ili filmom-obložene tablete.
software, stored in non-transient computer memory, operably processing the data transmitted by the remote data transmission system by the modem. 
softver za obradu podataka koji se prenose putem sustava za daljinski prijenos podataka (88) pomoću modema. Postupak obrade vode koji sadrži:
3 Excavating infected dentin Rule: sonde does not adhere anywhere in dentin 
Bušenje pogođenog dentina Pravilo: sonda se ne prima bilo gdje na tkivo dentina
In certain embodiments, the compound of Formula (J) is selected from: 
Spoj bilo kojeg od patentnih zahtjeva 1, 2 ili 7, koji je
The coating composition according to claim 15, wherein the polysiloxane-based binder system constitutes 50-90 % by dry weight of the coating composition. 
Smjesa za premaz prema patentnom zahtjevu 15, naznačena time da sustav veziva na bazi polisiloksana čini 5090% suhe mase smjese za premaz.
The solid dosage form according to claim 1, wherein valganciclovir hydrochloride is present in an amount from about 10% to about 90%, by weight of the total composition. 
Čvrsti dozirni oblik prema zahtjevu 1, naznačen time, da je valganciklovir-hidroklorid prisutan u količini od oko 10 do oko 90 masenih % od ukupnog sastava,
C1-C4 straight or branched chain alkyl group, optionally substituted with C3-C4 cycloalkyl group or fluorine, or 
-C4 alkilna skupina s ravnim ili razgranatim lancem, opcionalno supstituirana sa C3-C4 cikloalkilnom skupinom ili atomom fluora, ili
A compound having the following formula I: 
Spoj koji ima sljedeću formulu I:
However, in another embodiment of the invention, an additional humectant may be added, selected from a group comprising Glycerin, Sorbitol, Propylene glycol and the like, either singly or any combination thereof, to form a from about 5% (w/w) to 40% (w/w), preferably 30% (w/w), more preferably 25% (w/w). 
Postupak za proizvodnju kreme s fusidinskom kiselinom prema patentnom zahtjevu 9, naznačen time, da so nadalje ovlaživač dodaje u posudu za miješanje iz stupnja a u patentnom zahtjevu 9, a navedeni ovlaživač se odabire iz skupine koja sadrži glicerin, sorbitol, propilenglikol i slične, ili pojedinačno ili bilo koju njihovu kombinaciju, u količini od oko 5% (tež.) do 40% (tež.), prvenstveno 30% (tež.), pogodnije 25% (tež.).
precipitated protein) which will otherwise distort data. 
istaloženi protein) koje će inače iskriviti podatke.
In addition, some PCP-induced behaviours are reversed by certain atypical, but not typical antipsychotics (Geyer et al., Brain Res. Bull. 
Dodatno, neka ponašanja potaknuta s PCP mogu biti obrnuta određenim atipičnim, ali ne tipičnim antipsihoticima (Geyer i sur., Brain Res.
liquid tumour cancer; or hematological cancer; or colon cancer, gastric cancer, breast cancer, lung cancer, acute myeloid leukemia, thyroid cancer, ocular cancer, prostate cancer, ocular melanoma cancer, ovarian cancer, renal cancer, skin cancer, or squamous cell carcinoma. 
Tak tekućeg tumora; ili hematološki rak; ili rak debelog crijeva, gastrički rak, rak dojke, rak pluća, akutna mijeloidna leukemija, tiroidni Tak, očni rak, rak prostate, rak očnog melanoma, rak jajnika, rak bubrega, rak kože ili karcinom rožnatih stanica.
where m is an integer from 5 to 15; and 
gdje m je cijeli broj od 5 do 15; i
The material according to claim 1 or 2, wherein the vinyl chloride terpolymer is a vinyl chloride ethylene vinylacetate terpolymer (PVC/EVA terpolymer). 
Materijal prema patentnom zahtjevu 1 ili 2 naznačen time da je terpolimer vinil-klorida terpolimer vinil-klorid-etilen-vinil-acetata (PVC/EVA terpolimer).
These processes are necessary and required in the nature, but when wood is used for construction purposes, we would like to slow them down as much as possible. 
Ti procesi su nužni i potrebni u prirodi, ali kad se drvo upotrebljava za građevinske svrhe, željeli bismo ih usporiti što je više moguće.
the light chain framework sequence comprises a substitution at position 4 and/or position 47, optionally M4L and/or L47F; and/or 
humana kappa poskupina 1 konsenzualne okosnice sekvenci, koja ima supstituciju na poziciji 4 i/ili poziciji 47, opcijski M4L i/ili L47F; i/ili
which compound is further reacted with Et3SiH and trifluoro acetic acid followed by reaction with an acid to remove the N-piperidine protecting group and optionally to obtain a desired acid addition salt. 
\ a taj spoj dalje reagira s EGSiH i trifluor octenom kiselinom, nakon čega slijedi reakcija s kiselinom da se ukloni N- piperidin zaštitna skupina i po izboru da se dobije željena kisela adicijska sol.
Generally, the buffer and its components are as described for other lozenges of the invention. Further, the remaining components of the lozenge of this aspect are as described in relation to other lozenges of the invention, apart from the matrix. 
Generalno, pufer i njegove komponente su kao što su opisani za druge tablete izuma, Dalje, preostalo komponente tablete ovog aspekta su kao što su opisane u svezi sa drugim tabletama izuma, osim matriksa.
According to one preferred embodiment of the inventive process, the at least one acid having a pKa of less than or equal to 2.5 is selected from the group consisting of strong acids having a pKa value of less than or equal to zero at 25° C., and medium-strong acids having a pKa value of between zero and 2.5, inclusive, at 25° C. 
Postupak prema zahtjevu 1, naznačen time da barem jedna kiselina koja ima pK, od manje od ili jednako 2.5 je odabrana iz skupine koja sadrži jake kiseline koje imaju vrijednost pK, od manje od ili jednako nula kod 25 "C, te srednje-jake kiseline koje imaju vrijednost pK, od između nula i 2.5 kod 25 "C.
The packaging material of claim 1, wherein at least a part of the thermochromic ink is reversible. 
Pakirni materijal (1, 11) prema prethodnom zahtjevu 1, naznačen time, da termokromna tinta je reverzibilna.
and whereafter the compound of the Formula X obtained in the form of the free base in either solvated or non-solvated forms may be converted into a salt form and the compound of the Formula X obtained in the form of a salt may be converted into the free base or into the form of an alternative salt, if necessary. 
i gdje spoj sa formulom X, dobiven u obliku slobodne baze, može biti pretvoren u oblik soli, a spoj sa formulom X, dobiven u obliku soli, može biti pretvoren u slobodnu bazu ili u oblik alternativne soli, ako je potrebno. 12.
inhibition of proliferation of a cell expressing CLDN6, 
inhibira proliferaciju stanice koja eksprimira CLDN6,
A method of producing a piceatannol-containing composition according to claim 2 or 3, wherein the passion fruit seed is a raw passion fruit seed or a dried passion fruit seed, which is obtained by drying the raw passion fruit seed. 
Postupak proizvodnje sastava koji sadrži piceatanol, prema bilo kojem od zahtjeva 7 do 9, naznačen time, da sjeme Passiflora edulis sims je sirovo sjeme Passiflora edulis sims, ili je to osušeno sjeme Passiflora edulis sims, koje je dobiveno sušenjem sirovog sjemena Passiflora edulis sims.
a clearance receptor, or fragment thereof, wherein the clearance receptor blocks binding of the recombinant FVIII protein to FVIII clearance receptors; 
(i) receptora za čišćenje, ili njegovog fragmenta, pri čemu receptor za čišćenje blokira vezanje rekombinantnog FVIII proteina na FVIII receptore za čišćenje;
A package as claimed in Claim 4, wherein the main wall (26) of the stiffener (25) is positioned contacting the front wall of the group (4) of cigarettes, and comprises a top window (28). 
Pakiranje u skladu s patentnim zahtjevom 4, naznačeno time, da je glavna stjenka (26) elementa za učvršćivanje (25) postavljena tako da dodiruje prednju stjenku skupine (4) cigareta i sadrži gornji otvor (28).
A combretastatin compound, or a pharmaceutically acceptable salt thereof, for use in treating a non-solid hematopoietic neoplasm wherein the hematopoietic neoplasm is a myeloid neoplasm, and wherein the combretastatin compound is combretastatin A-1 diphosphate (CA1dP): or a pharmaceutically acceptable salt thereof. 
Kombretastatinski spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u liječenju nečvrste krvotvorne novotvorine, naznačen time što je krvotvorna novotvorina mijeloidna novotvorina, te što je kombretastatinski spoj kombretastatin A-1-difosfat (CA1dP):
wherein, R3 is substituted 4-12 membered aromatic heterocyclic radical, the substituent on the substituted heteroaromatic ring is —H, C1-C6 alkyl, aryl, —CF3 or 5-10 membered aromatic heterocyclic radical; and the number of heteroatoms on the aromatic heterocyclic radical is 1 to 4, and the heteroatom is N, O or S; 
Rs je supstituirani 4-12-člani aromatski heterociklični radikal, HE. ili HR P20181172 T1 supstituent na supstituiranom heteroaromatskom prstenu je -H, Ci - C& alkil, aril, -CFa, ili 5-10-člani aromatski heterociklični radikal; te je broj heteroatoma na aromatskom heterocikličnom radikalu 1 do 4, i heteroatom je N, O ili S;
a solvent is added to the plant components reduced in size to extract the active ingredient (a.i.) from the plant components, wherein the solvent used is water and/or an organic solvent wherein the organic solvent is selected of the group consisting of ketones, alcohols, esters and halogenated hydrocarbons, 
(b) otapalo se dodaje u biljne dijelove smanjene veličine, kako bi se ekstrahirao djelatni sastojak iz dijelova biljke, pri čemu se kao otapalo koristi voda i/ili organsko otapalo, dok je organsko otapalo odabrano iz skupine koju čine: ketoni, alkoholi, esteri 1 halogenirani ugljikohidrati,
administering to a donor of said bone marrow said peptide; 
(a) primjena tog peptida donoru koštane srži;
The pharmaceutical composition for use according to claim 2, wherein: 
Farmaceutski sastav za uporabu prema zahtjevu 2, naznačen time, da:
A 2.0 mg/mL, solution can be made by dilution of 50.0 mL of the 4.0 mg/mL solution to 100.0 mL with placebo. 
Otopina 2.0 mg/mL može se pripraviti razrjeđivanjem 50.0 mL 4.0 mg/mL otopine u 100.0 mL sa placebom.
is prepared by reacting the compounds of the formula (XVI a,b) 
(XVIII), se pripravlja reakcijom spojeva s formulom (XVI a,b) N
Furthermore, KW-6002 significantly improves motor impairment induced in non-human primates by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), without causing dyskinesias, that is commonly described for long-term treatment with the dopamine agonist L-dopa (Kanda et al, 1998, Ann. 
Nadalje, KW-6002 značajno poboljšava motoričko oštećenje inducirano kod primata s MPTP (1-meti-4-fenil-1,2,3,6-tetrahidropiridin), bez dodatnog uzrokovanja diskinezije, koja je uobičajeno opisana kod dugotrajnog tretiranja s dopaminskim agonistima L- dopa (Kanda et al, 1998, Ann.
Hydrogen sulfide scavenging additive capable of scavenging hydrogen sulfide in hydrocarbons by forming water soluble scavenged products which are capable of getting separated from hydrocarbon even at acidic pH without causing fouling and decomposition problems, wherein the scavenging additive consists of aldehyde and polyethylene glycol [PEG], and wherein said aldehyde is glyoxylic acid. 
PATENTNI ZAHTJEVI Aditiv za čišćenje vodik sulfida sposoban čistiti vodik sulfid u ugljikovodicima stvaranjem proizvoda za čišćenje topivih u vodi koji su sposobni odvojiti se od ugljikovodika čak i u kiselom pH bez stvaranja problema onečišćenja i raspadanja, pri čemu se aditiv za čišćenje sastoji od aldehida 1 polietilen glikola (PEG), i pri čemu navedeni je aldehid glioksilna kiselina.
bringing the gel obtained in step a) into contact with an effective amount of at least one endogenous polyamine to form a mixture, wherein said at least one endogenous polyamine is used in a content between 0.1% and 3% by number of moles of the at least one endogenous polyamine relative to the number of moles of hyaluronic acid, 
dovođenje gela dobivenog u koraku a) u kontakt s učinkovitom količinom najmanje jednog endogenog poliamina, te po izboru u prisutnosti dodatnog sredstva za umrežavanje,
Trifloroacetic acid (0.5 mL) was added in one portion and the resulting solution stirred for 1 h at room temperature. 
Triflorooctenu kiselinu (0,5 ml) doda se u jednom obroku, a dobivenu otopinu miješa 1 sat na sobnoj temperaturi.
The anti-VEGF antibody for use of claim 1, or the use of claim 2, wherein the anti-VEGF antibody is bevacizumab and the chemotherapy is capecitabine, and optionally wherein the administration of capecitabine is 1000 mg/m2 oral twice daily on Days 1-14 of each 3-week cycle and the administration of bevacizumab is 15mg/kg IV on day 1 of each 21-day cycle. 
Protutijelo anti-VEGF za uporabu prema zahtjevu 4, naznačeno time, da je primjena kapecitabina oralno dva puta dnevno po 1000 mg/m2 od prvog do četrnaestog dana svakog ciklusa od tri tjedna i primjena bevacizumaba je po 15 mg/kg IV prvoga dana svakog ciklusa od dvadesetjednog dana.
In the following, such protein is also called “purified IL-18BP”. 
U nastavku takav protein se naziva «pročišćeni IL-18BP».
In some embodiments, the crystalline form of Rotigotine comprises at least 50% of form II. 
Rotigotin ljekovita supstanca koja sadrži najmanje 50% polimorfnog oblika Rotigotina kako je definirano u bilo kojem od patentnih zahtjeva 1-2.
connection opened and right and/or left exhaust tract aperture partially closed; and/or 
zajednički otvor za spajanje (91) je otvoren i desni i/ili ispušni krak otvora je djelomično zatvoren i/ili
A metered dose inhaler containing a pharmaceutical composition as defined in any of claims 1 to 28, wherein the metered dose inhaler exhibits a delivered dose uniformity ("DDU") for the suspension formulation selected from a DDU of ± 30%, or better, a DDU of ± 25%, or better, and a DDU of ± 20%, or better, for the active agent throughout emptying of an MDI canister. A pharmaceutical composition as defined in any one of claims 1 to 28 for use in medicine. 
Ko-suspenzija prema bilo kojem od patentnih zahtjeva 1 do 28 naznačena time što se upotrebljava u postupku respiratornog davanja aktivnog sredstva pacijentu, te postupak sadrži: osiguravanje inhalatora s odmjerenom dozom koji sadrži spremnik koji sadrži ko-suspenziju kako je definirana u bilo kojem od zahtjeva 1 do 28; i davanje ko-suspenzije pacijentu korištenjem inhalatora s odmjerenom dozom.